These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 24156018)

  • 81. NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells.
    Rocha CR; Kajitani GS; Quinet A; Fortunato RS; Menck CF
    Oncotarget; 2016 Jul; 7(30):48081-48092. PubMed ID: 27344172
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Local delivery of cancer-cell glycolytic inhibitors in high-grade glioma.
    Wicks RT; Azadi J; Mangraviti A; Zhang I; Hwang L; Joshi A; Bow H; Hutt-Cabezas M; Martin KL; Rudek MA; Zhao M; Brem H; Tyler BM
    Neuro Oncol; 2015 Jan; 17(1):70-80. PubMed ID: 25053853
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
    Nitta Y; Shimizu S; Shishido-Hara Y; Suzuki K; Shiokawa Y; Nagane M
    Cancer Med; 2016 Mar; 5(3):486-99. PubMed ID: 26778701
    [TBL] [Abstract][Full Text] [Related]  

  • 84. MiR-139 inhibits Mcl-1 expression and potentiates TMZ-induced apoptosis in glioma.
    Li RY; Chen LC; Zhang HY; Du WZ; Feng Y; Wang HB; Wen JQ; Liu X; Li XF; Sun Y; Yang DB; Jiang T; Li YL; Jiang CL
    CNS Neurosci Ther; 2013 Jul; 19(7):477-83. PubMed ID: 23551751
    [TBL] [Abstract][Full Text] [Related]  

  • 85. LRRC8A potentiates temozolomide sensitivity in glioma cells via activating mitochondria-dependent apoptotic pathway.
    Yang C; He L; Chen G; Ning Z; Xia Z
    Hum Cell; 2019 Jan; 32(1):41-50. PubMed ID: 30426452
    [TBL] [Abstract][Full Text] [Related]  

  • 86. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
    Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
    Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Lithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signalling.
    Han S; Meng L; Jiang Y; Cheng W; Tie X; Xia J; Wu A
    Br J Cancer; 2017 May; 116(10):1302-1311. PubMed ID: 28359080
    [TBL] [Abstract][Full Text] [Related]  

  • 88. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
    Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S
    Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
    Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
    Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells.
    Kanzawa T; Germano IM; Komata T; Ito H; Kondo Y; Kondo S
    Cell Death Differ; 2004 Apr; 11(4):448-57. PubMed ID: 14713959
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation.
    Van Nifterik KA; Van den Berg J; Slotman BJ; Lafleur MV; Sminia P; Stalpers LJ
    J Neurooncol; 2012 Mar; 107(1):61-7. PubMed ID: 22037799
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide.
    Li H; Yuan X; Yan D; Li D; Guan F; Dong Y; Wang H; Liu X; Yang B
    Cell Physiol Biochem; 2017; 42(3):1192-1201. PubMed ID: 28668966
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems.
    Toren A; Pismenyuk T; Yalon M; Freedman S; Simon AJ; Fisher T; Moshe I; Reichardt JK; Constantini S; Mardor Y; Last D; Guez D; Daniels D; Assoulin M; Mehrian-Shai R
    Oncotarget; 2016 Nov; 7(46):74860-74871. PubMed ID: 27556862
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis.
    Sehm T; Rauh M; Wiendieck K; Buchfelder M; Eyüpoglu IY; Savaskan NE
    Oncotarget; 2016 Nov; 7(46):74630-74647. PubMed ID: 27612422
    [TBL] [Abstract][Full Text] [Related]  

  • 96. TMZ regulates GBM stemness via MMP14-DLL4-Notch3 pathway.
    Ulasov IV; Mijanovic O; Savchuk S; Gonzalez-Buendia E; Sonabend A; Xiao T; Timashev P; Lesniak MS
    Int J Cancer; 2020 Apr; 146(8):2218-2228. PubMed ID: 31443114
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Glioma initiating cells form a differentiation niche via the induction of extracellular matrices and integrin αV.
    Niibori-Nambu A; Midorikawa U; Mizuguchi S; Hide T; Nagai M; Komohara Y; Nagayama M; Hirayama M; Kobayashi D; Tsubota N; Takezaki T; Makino K; Nakamura H; Takeya M; Kuratsu J; Araki N
    PLoS One; 2013; 8(5):e59558. PubMed ID: 23704872
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity.
    Hirose Y; Kreklau EL; Erickson LC; Berger MS; Pieper RO
    J Neurosurg; 2003 Mar; 98(3):591-8. PubMed ID: 12650433
    [TBL] [Abstract][Full Text] [Related]  

  • 99. miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1.
    Wang J; Sai K; Chen FR; Chen ZP
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):147-58. PubMed ID: 23645289
    [TBL] [Abstract][Full Text] [Related]  

  • 100. MicroRNA-34a-5p suppresses tumorigenesis and progression of glioma and potentiates Temozolomide-induced cytotoxicity for glioma cells by targeting HMGA2.
    Ma S; Fu T; Zhao S; Gao M
    Eur J Pharmacol; 2019 Jun; 852():42-50. PubMed ID: 30851271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.